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ORIGINAL ARTICLE
Prognostic factors of local control and disease free survival in centrally located
non-small cell lung cancer treated with stereotactic body radiation therapy
Marloes Duijma, No€elle C. van der Voort van Zypb, Patrick V. Grantona, Paul van de Vaartb, Mirjam E. Mastb,
Esther Oomen-de Hoopa, Mischa S. Hoogemana and Joost J. Nuyttensa
aDepartment of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands; bDepartment of Radiation Oncology,
Haaglanden MC, The Hague, The Netherlands
ABSTRACT
Background: Stereotactic body radiation therapy (SBRT) results in high local control (LC) rates in
patients with non-small cell lung cancer (NSCLC). For central lung tumors, risk-adapted fractionation
schedules are used and underdosage to the Planned Target Volume (PTV) is often accepted to respect
the dose constraints of the organs at risk in order to avoid high rates of toxicity. The purpose of this
study was to analyze the effect of PTV underdosage and other possible prognostic factors on local-
and disease control after SBRT in patients with central lung tumors.
Material and Methods: Patients with centrally located NSCLC treated with SBRT were included. The
doses were converted into biologically equivalent dose using a/b-value of 10 Gy (BED10). Underdosage
to the PTV was defined as the (percentage of) PTV receiving less than 100Gy BED10; (%)PTV < 100
BED10. Potential prognostic factors for LC and Disease Free Survival (DFS) were evaluated using Cox
regression analysis.
Results: Two hundred and twenty patients received 12 fractions of SBRT. LC-rates were 88% at
2 years and 81% at 3 years. Twenty-seven patients developed a local recurrence. Both the PTV < 100
BED10 and %PTV < 100 BED10 were not prognostic for LC. Tumor size and forced expiratory volume in
1 second (FEV1) were independently prognostic for LC. Disease progression was reported in 75 patients
with DFS-rates of 66% at 2 years and 56% at 3 years. Disease recurrence was independent significantly
associated with larger tumor diameter, lower lobe tumor location and decreased FEV1. Grade 4–5 tox-
icity was reported in 10 patients (8 with ultra-central tumors) and was fatal in at least 3 patients.
Conclusion: Decrease in tumor coverage was not correlated with the local recurrence probability. The
LC and DFS were promising after SBRT of centrally located NSCLC with tumor size, FEV1 and tumor
location (for DFS only) as prognostic factors.
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Introduction
Stereotactic body radiation therapy (SBRT) is the golden
standard in patients having early stage non-small cell lung
cancer (NSCLC) not suitable for surgery [1,2]. Over more than
15 years ago, reports of high-grade toxicity after stereotactic
radiotherapy resulted in the definition of a ‘central lung
tumor’ together with the proposal of risk-adapted fraction-
ation schedules [3,4] and accompanying dose constraints for
organs at risk (OAR) [5]. Despite these risk-adapted schedules
and dose constraints, high-grade toxicity has been reported
in recent prospective studies [6–8]. This resulted in a higher
awareness for toxicity in the treatment of central lung
tumors, wherein prioritizing dose constraints of the OAR over
tumor coverage is recommended.
Additionally, a clear fractionation consensus for centrally
located lung tumors is missing. As such, risk-adapted sched-
ules vary between institutes. These different risk-adapted
schedules are not all resulting in the same biologically
equivalent dose (using an a/b-ratio of 10Gy; BED10). Multiple
studies report high local control (LC) rates when prescribing
a minimum of 100Gy BED10 [9–12]. However, a fractionation
schedule with a minimum dose of 100Gy BED10 covering
more than 95% of the Planned Target Volume (PTV), can still
result in a wide variety of dose distributions to the PTV. This
variety of dose in combination with the heterogeneity of
stereotactic treatment plans, asks for additional PTV parame-
ters to define the optimal treatment plan that gives
adequate local tumor control [13]. Therefore, additional PTV
parameters, such as Dmean [13,14] and D95% [14], have been
proposed by various studies in the stereotactic treatment of
NSCLC. Additionally, the ICRU 91 suggests the use of the
median dose to the PTV (D50%) as a representative absorbed-
dose value for the PTV [15].
Taking the increased priority of the OAR dose constraints
and the previous mentioned studies in mind, the question
can be raised whether only a prescribed dose of more than
100Gy BED10 is enough for adequate tumor control.
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Moreover, prioritizing the OAR constraints can result in a
reduced PTV coverage and the effect of this underdosage on
the LC probability is unknown. The purpose of this research
is to determine the effect of reduced tumor coverage and
other possible prognostic factors on local and disease control
in patients with centrally located NSCLC treated with SBRT.
Material and methods
We identified patients having T1-4N0M0 NSCLC treated
between 2006 and 2016 with risk-adaptive stereotactic radio-
therapy in 2 Dutch centers: Erasmus Medical Center (EMC)
and Haaglanden Medical Center (HMC). Tumors were consid-
ered central when the tumor was located within 2 cm of the
esophagus and/or the bronchial structures (trachea, main
bronchus, bronchus intermedius or upper-, middle- or lower-
lobe bronchi). Patients were excluded if they had: a second
lung nodule, previous radiation with overlapping fields,
chemotherapy during SBRT and if they did not have any fol-
low-up. Diagnostic work-up consisted of a PET scan. An MRI
scan of the brain was not performed in these patients with-
out nodal disease.
Treatment planning and delivery of both centers have
been previously described [16,17]. Briefly, the treatment in
the HMC was initially delivered with a stereotactic linear
accelerator (Novalis, Brainlab AG, Munich Germany), that was
replaced by a linear accelerator with cone-beam CT-guidance
(Elekta AB, Stockholm, Sweden) in 2013. Patients were
treated with 60Gy in 8 fractions 3 times a week or, 60 Gy in
12 fractions 4 times a week if the PTV overlapped with or
was too close to the OAR. The PTV consisted of an Internal
Target Volume (ITV) that was expanded with 5mm (6mm in
craniocaudal direction) for the Novalis linear accelerator and
6mm in all directions for the Elekta linear accelerator. Until
2014, the ITV was created by expanding the Gross Tumor
Volume (GTV) based on 6 scans taken randomly during the
breathing cycle. Thereafter, the ITV was created by contour-
ing the tumor in 10 respiratory phases of the 4D CT scan.
The treatment dose was prescribed to the 100% isodose line
and the maximum dose was not allowed to exceed 140%. At
least 95% of the PTV had to receive 100% of the prescribed
dose and 99% of the PTV had to receive 90% of the pre-
scribed dose. In EMC, patients were treated with the
Cyberknife Robotic Radiosurgery System (Accuray Inc,
Sunnyvale, AC) with 5 fractions of 9–12Gy or, when the
tumor was close to the esophagus, 6–7 fractions of 7–8Gy,
except in 2 patients who received 3 fractions of 20Gy. The
PTV consisted of the GTV plus 5mm. The dose to the PTV
was prescribed to the 70–90% isodose line covering at least
95% of the PTV. At both institutions, underdosage was
allowed in order to meet the dose constraints of the OAR
(Table S1 in Supplementary materials) or an acceptable dose
to the OAR at the discretion of the treating physician.
Follow-up was generally performed 3weeks, 3, 6, 12, 18
and 24months following SBRT and annually thereafter.
Patient records from hospitals and general practitioners were
screened for disease control, survival status and toxicity. A
local recurrence was defined as a recurrence within or
adjacent to the PTV. Disease progression was defined as a
tumor recurrence in any part of the body. In the absence of
a biopsy, (local) tumor recurrence was defined as a 20%
increase in tumor size on the CT scan compared with the
previous CT scan according to the Response Evaluation
Criteria In Solid Tumors (RECIST, version 1.0). In addition, a
corresponding avid lesion on the PET scan was required. In
order to visualize the location of all the local recurrences, we
contoured the center of the treated tumor as a small 3D cir-
cle (diameter 7mm) on one CT scan. Local control was calcu-
lated from the start of SBRT until the moment of diagnosis
of the local recurrence. For patients without an event, the
last date of a follow-up visit in the hospital was used. Overall
survival and disease free survival (DFS) were calculated using
the first date of SBRT and the date of death or disease pro-
gression, respectively. For patients without an event, the last
date of follow-up visit or the last date of contact was used.
As the last date of follow-up contact was used, death was
not a competing risk for disease recurrence. Underdosage of
the tumor is described as absolute and relative volume of
the PTV receiving less than 100Gy BED10. All cases with
grade 3 or higher toxicity according to the definition of the
Common Terminology Criteria for Adverse Events (version
4.03) were scored. Toxicity was considered acute if it
Table 1. Patient- and tumor-characteristics (n¼ 220).
n (%)/median (IQR, range)





No COPD 39 (18%)
GOLD I–II 113 (51%)













No pathology available 91 (42%)
Squamous cell carcinoma 68 (31%)
Adenocarcinoma 40 (18%)
Large cell carcinoma 18 (8%)
Different 3 (1%)




Prescribed amount of fractions
3 Fractions of 20 Gy 2 (1%)
5 Fractions of 9/10/11/12 Gy 82 (37%)
6 Fractions of 7/8 Gy 17 (8%)
7 Fractions of 7 Gy 18 (8%)
8 Fractions of 7.5 Gy 69 (31%)
12 Fractions of 5 Gy 32 (15%)
Tumor diameter (mm) 44 (33–58, 9–105)
COPD: Chronic Obstructive Pulmonary Disease; Gy: Gray; IQR: interquartile
range; PTV: Planned Target Volume.
810 M. DUIJM ET AL.
occurred within 3months from the start of the SBRT and late
if it occurred thereafter.
Because of variations in the treatment schedules, all doses
were converted into a BED10 using the following formula:
BED ¼ D  1þ da=b
 
with D ¼ total dose, d ¼ dose per
fraction and a/b-value is 10Gy. Dosimetric PTV parameters
were derived from the dose volume histogram (DVH) of each
patient: maximum and minimum point dose (Dmax, Dmin),
mean dose (Dmean), dose to 2/50/98 percent of the PTV (D2%/
D50%/D98%) and volume of the PTV receiving less than 100Gy
BED10 (PTV < 100 BED10).
Cox regression was used to determine LC and DFS and to
test possible prognostic factors for (local) disease control.
The following factors were entered into the univariate analy-
ses: age, gender, previous (lung)malignancies, WHO status (0
versus  1), Charlson Comorbidity Score (CCS; 0–2 versus 
3), Chronic Obstructive Pulmonary Disease (COPD; GOLD 0–1
versus 2–4), Forced Expiratory Volume in 1 second (FEV1),
endobronchial tumor location, availability of pathology, local-
ization of the tumor in the upper/middle lobe or mediasti-
num versus the lower lobe, disease stage (TNM 8th; IA–IIA
versus IIB–IIIA), tumor size, PTV volume, prescribed dose
(<100Gy BED10 versus 100Gy BED10), Dmax BED10, Dmin
BED10, Dmean BED10, D2% BED10, D50% BED10 (as a continuous
variable and dichotomized to <100Gy BED10 versus 100Gy
BED10), D98% BED10, PTV < 100 BED10 and percentage of the
PTV receiving less than 100Gy BED10 (%PTV < 100 BED10).
The univariate analyses was followed by a multivariate analy-
ses (MVA) with backward selection for all factors having a p-
value < .20. When multiple correlating variables were signifi-
cant in univariate analyses, only the factor with the highest
clinical relevance was entered in the MVA. The proportional
hazards assumption, assuming that the hazard between the
groups is constant over time, was checked for each variable
that was entered into the Cox regression. Kaplan-Meier esti-
mates were calculated for all clinical outcomes and curves
were compared using log-rank tests. Tumor size was not
only analyzed as a continuous variable, but also dichotom-
ized with a cutoff of 5 cm, such that we could examine the
relevance of this cutoff criteria used by the RTOG 0813 study
for inclusion (in which tumors had to be 5 cm) [8]. In all
analyses a p-value  .05 was considered statistically signifi-
cant. Analyses were performed using IBM SPSS statistics ver-
sion 25.0.0.1 software package (SPSS Inc., Chicago, IL). This
retrospective study received approval from the medical eth-
ical committees of both centers.
Results
For this analysis 220 patients were eligible. Patient- and
treatment characteristics are shown in Table 1. The diagnosis
was confirmed by pathology in 58% of patients. All but one
patient had a diagnostic PET-CT scan. In this patient path-
ology was available. The majority of the patients was diag-
nosed with stage I (38%) or stage II lung cancer (52%). The
most commonly used fractionation schedules were 5 frac-
tions (37%), 8 fractions (31%) and 12 fractions (15%).
Figure 1. Pattern of recurrence: (A) anterior view and (B) lateral view. Small light blue circles represent the center of mass of each tumor reporting local recurrence.
Color legend organs at risk: orange: esophagus, dark blue: bronchial tree (trachea, main bronchus, bronchus intermedius or upper-, middle- or lower- lobe bronchi),
light red: aorta, dark red: heart.
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Local control rates were 92% at 1 year, 88% at 2 years
and 81% at 3 years. Twenty-seven patients (12%) were
diagnosed with a local recurrence. No clear pattern of
local relapse could be visualized when delineating all
recurrences on one CT scan (Figure 1). Relative and abso-
lute PTV underdosage were both not prognostic for a local
recurrence (PTV <100 BED10 p ¼ .593 and %PTV <100
BED10 p ¼ .127). The median PTV receiving less than
100Gy BED10 was 4.2 cc in patients with a recurrence com-
pared to 1.2 cc in patients without a recurrence. The
median percentage of the PTV receiving less than 100Gy
BED10 was the same in patients with and without a local
recurrence (both 2%, Table 2).
Factors prognostic for the development of a local recur-
rence using univariate analysis were a larger tumor diameter
(continuous variable), higher disease stage, a tumor localized
in the lower lobe and a prescribed dose of <100Gy BED10
(Table 2). The 1 year LC rate was significantly higher for
tumors <5 cm compared to tumors 5 cm (96% versus 84%,
p< .001, Figure 2a). When the prescribed dose was lower
than 100Gy BED10, patients were twice as likely to develop a
local recurrence: Hazard Ratio (HR) 2.24, 95% Confidence







median (IQR)/n (%) Hazard Ratio (95%CI) p-value
Age 76 (68–81) 71 (62–77) 0.97 (0.93–1.01) .091
FEV1
a 64 (50–80) 60 (48–72) 0.98 (0.96–1.01) .119
Gender
Male 117 (89%) 14 (11%) 1
Female 76 (85%) 13 (15%) 1.18 (0.55–2.51) .672
Localization of tumor
UMM 140 (90%) 16 (10%) 1
Lower 53 (83%) 11 (17%) 2.26 (1.05–4.88) .038
WHO statusb
0 64 (86%) 10 (14%) 1
1–4 120 (88%) 17 (12%) 1.12 (0.51–2.45) .775
COPDc
0–1 63 (91%) 6 (9%) 1
2–4 125 (87%) 19 (13%) 1.30 (0.52–3.25) .580
Pathology available
No 83 (91%) 8 (9%) 1
Yes 110 (85%) 19 (15%) 1.97 (0.86–4.51) .107
CCS
0–2 113 (88%) 15 (12%) 1
3 80 (87%) 12 (13%) 1.14 (0.53–2.44) .741
Previous malignanciesd
No 115 (86%) 18 (14%) 1
Yes 78 (90%) 9 (10%) 0.84 (0.38–1.87) .666
Previous lungcad
No 175 (89%) 22 (11%) 1
Yes 18 (78%) 5 (22%) 1.51 (0.57–4.02) .404
Endobronchial tumor
No 154 (87%) 23 (13%) 1
Yes 39 (91%) 4 (9%) 1.05 (0.36–3.08) .923
Disease stage
IA–IIA 122 (93%) 9 (7%) 1
IIB–IIIA 71 (80%) 18 (20%) 4.43 (1.97–9.94) <.001
Tumordiameter (mm) 42 (32–54) 54 (38–62) 1.04 (1.02–1.06) .001
PTV volume (cc) 75 (42–135) 118 (50–157) 1.00 (1.00–1.01) .054
PTV < 100 BED10 (cc) 1.2 (0.2–27.4) 4.2 (0.4–75.4) 1.00 (1.00–1.00) .593
%PTV < 100 BED10 2% (0–38%) 2% (1–55%) 2.26 (0.79–6.43) .127
Prescribed dose BED10
<100 56 (84%) 11 (16%) 1
100 137 (90%) 16 (10%) 0.45 (0.20–0.98) .045
PTV Dmax BED10 144 (127–175) 139 (122–157) 0.99 (0.98–1.01) .193
PTV D2% BED10 139 (121–163) 134 (115–152) 0.99 (0.98–1.01) .203
PTV Dmean BED10 122 (102–136) 115 (97–132) 0.99 (0.97–1.01) .278
PTV D50% BED10 123 (103–137) 117 (98–132) 0.99 (0.97–1.01) .279
PTV D98% BED10 100 (84–105) 92 (77–104) 0.99 (0.97–1.01) .383
PTV Dmin BED10 75 (64–90) 72 (56–85) 0.99 (0.97–1.01) .186
PTV D50% BED10
<100 39 (85%) 7 (15%) 1
100 154 (89%) 20 (11%) 0.49 (0.21–1.12) .092
a24 cases missing; b9 cases missing; c7 cases missing; dproportional hazard assumption is violated.
BED10: Biologically Effective Dose using a/b-ratio of 10 Gy; CCS: Charlson Comorbidity Score; COPD: Chronic Obstructive Pulmonary Disease; Dmax: maximum
point dose; Dmean: mean dose; Dmin: minimum point dose; D..%: dose to .. percent of the PTV; FEV1: Forced Expiratory Volume in 1 second; NSCLC: non-small
cell lung cancer; PTV: Planned Target Volume; PTV < 100 Gy BED10: volume of the PTV which is receiving less than 100 Gy BED10; SBRT: Stereotactic Body
Radiation Therapy; UMM: upper/middle lobe or mediastinum; %PTV < 100 Gy BED10: percentage of the volume of the PTV which is receiving less than
100 Gy BED10.
Italic values indicate significant p .05.
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Interval (CI) 1.02–4.95, p ¼ .045. A PTV D50% of <100Gy
BED10 was not prognostic for local recurrence (LC at 1 year
85% for D50% of <100Gy BED10 versus 93% for D50% of
100Gy BED10, p ¼ .139, Figure 2b).
The MVA included age, localization of the tumor (upper/
middle lobe or mediastinum versus lower lobe), FEV1, avail-
ability of pathology (no versus yes), tumor diameter, %PTV <
100 BED10, PTV Dmin BED10, prescribed dose in BED10
(<100Gy versus 100Gy) and PTV D50% BED10 (<100Gy ver-
sus 100Gy). Factors independently prognostic for local
tumor recurrence in MVA were larger tumor size and lower
FEV1: HR tumor diameter 1.04, 95% CI 1.02–1.06, p ¼ .001
and HR FEV1 0.97, 95% CI 0.95–1.00, p ¼ .031.
Disease progression was reported in 75 patients (34%).
The DFS was 73% at 1 year, 66% at 2 years and 56% at
3 years. Disease free survival was significantly better for
patients with tumors smaller than 5 cm (p < .001, Figure 2c).
There was a trend for increased DFS in patients who received
PTV D50% of 100Gy BED10 (p ¼ .053, Figure 2d). Factors
prognostic for progressive disease using univariate analyses
were lower FEV1, larger tumor size (continuous), larger PTV
volume, tumors located in the lower lobe and disease stage
IIB–IIIA (Table 3). Factors prognostic for progressive disease
using multivariate analyses were larger tumor diameter (HR
1.03, 95% CI 1.02–1.04, p < .001), lower FEV1 (HR 0.98, 95%
CI 0.97–0.99, p ¼ .004) and localization of the tumor in the
lower lobe (HR 1.87, 95% CI 1.12–3.11, p ¼ .017).
Thirty-eight percent of the patients had a tumor overlap-
ping or adjacent to the proximal bronchial tree (PBT) and/or
the esophagus; 67 patients to the PBT, 8 to the esophagus
and 9 patients to both. The incidence of the local recur-
rences of these ultracentral tumors was only slightly higher
compared to the central tumors: 14% versus 11%. The LC at
1 year was 91% for ultracentral tumors and 92% for central
tumors (p ¼ .095). Although these comparable LC rates,
almost all cases (8 of 10) of grade 4–5 toxicity occurred in
the group of ultracentral tumors. These eight patients all had
an ultracentral tumor due to proximity to the PTB. Details of
the grade 4–5 toxicity cases are outlined below. In the group
of 10 patients reporting grade 4–5 toxicity greater
Figure 2. Kaplan–Meier curves for local control (A,B) and disease free survival (C,D).
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concession was done to the %PTV <100 BED10. The median
%PTV <100 BED10 was 26% in patients with grade 4–5 tox-
icity versus 2% in the rest of the patients. Three of the 10
patients received <100Gy BED10 in more than 90% of the
volume of the PTV and in three patients less than 2.5% of
the PTV received <100Gy BED10.
One patient had grade 4 toxicity and nine patients had
grade 5 toxicity. Grade 4 was scored because of a necrotic
post obstruction pneumonia. The PET scan showed a fibrotic
mass most likely caused by the radiation. Of the nine
patients with grade 5 toxicity, three deaths were likely due
to SBRT, while six deaths were possibly related to SBRT. The
three patients with a death likely related to SBRT had
hemoptoe 4.5, 9 and 22months after treatment. The tumor
was adjacent to the intermediate bronchus or main bron-
chus, and there was no evidence of disease recurrence in
these patients. Three other patients, having their death pos-
sibly related to SBRT, died due to fatal hemoptoe in the pres-
ence of disease recurrence. In this group, two patients did
not have an ultracentral tumor. In the last three patients,
respiratory failure was the cause of death which was also
possibly related to the SBRT. One patient died due to a
COPD exacerbation and two patients died of atelectasis in
the lung in combination with disease progression. SBRT
could not be excluded as a cause of death in these last three
patients. Grade 3 or higher toxicity was scored in 12%
(n¼ 27) of the patients. The overall survival was 55% at
2 years, 42% at 3 years and 26% at 5 years.
Table 3. Results of the Cox regression analyses focusing on patient- and dosimetric factors prognostic for disease free survival for patients with T1-4N0M0 NSCLC
treated with SBRT.
Univariate analysis
Characteristic Disease control median (IQR)/n (%) Disease progression median (IQR)/n (%) Hazard Ratio (95%CI) p-value
Age 77 (70–81) 72 (64–79) 0.98 (0.95–1.00) .066
FEV1
a 65 (50–84) 60 (49–72) 0.99 (0.97–1.00) .047
Gender
Male 83 (63%) 48 (37%) 1
Female 62 (70%) 27 (30%) 0.77 (0.48–1.24) .281
Localization of tumor
UMM 112 (72%) 44 (28%) 1
Lower 33 (52%) 31 (48%) 2.36 (1.49–3.74) <.001
WHOb
0 50 (68%) 24 (32%) 1
1–4 91 (66%) 46 (34%) 1.26 (0.77–2.07) .354
COPDc
0–1 52 (75%) 17 (25%) 1
2–4 88 (61%) 56 (39%) 1.41 (0.82–2.42) .220
PA available
No 61 (67%) 30 (33%) 1
Yes 84 (65%) 45 (35%) 1.22 (0.77–1.94) .393
CCS
0–2 84 (66%) 44 (34%) 1
3 61 (66%) 31 (34%) 0.96 (0.61–1.53) .877
Previous malignancies
No 85 (64%) 48 (36%) 1
Yes 60 (69%) 27 (31%) 0.86 (0.54–1.38) .527
Previous lungcad
No 131 (66%) 66 (34%) 1
Yes 14 (61%) 9 (39%) 0.92 (0.46–1.86) .821
Endobronchial tumor
No 114 (64%) 63 (36%) 1
Yes 31 (72%) 12 (28%) 1.04 (0.56–1.94) .895
Disease stage
IA–IIA 101 (77%) 30 (23%) 1
IIB–IIIA 44 (49%) 45 (51%) 3.23 (2.03–5.13) <.001
Tumordiameter (mm) 38 (30–51) 51 (39–61) 1.03 (1.02–1.04) <.001
PTV volume (cc) 64 (39–129) 102 (67–154) 1.00 (1.00–1.00) .003
Prescribed dose BED10
<100 41 (61%) 26 (39%) 1
100 104 (68%) 49 (32%) 0.70 (0.43–1.13) .144
PTV Dmax BED10 144 (130–173) 140 (122–176) 1.00 (0.99–1.00) .314
PTV D2% BED10 140 (122–164) 136 (115–163) 1.00 (0.99–1.00) .258
PTV Dmean BED10 122 (102–136) 120 (100–135) 0.99 (0.98–1.01) .253
PTV D50% BED10 123 (103–136) 120 (101–136) 0.99 (0.98–1.01) .252
PTV D98% BED10
d 101 (85–106) 92 (82–105) 0.99 (0.98–1.01) .244
PTV Dmin BED10 77 (64–89) 73 (62–89) 0.99 (0.98–1.01) .307
PTV D50% BED10
<100 28 (19%) 18 (24%) 1
100 117 (81%) 57 (76%) 0.60 (0.35–1.01) .056
a24 cases missing; b9 cases missing; c7 cases missing; dproportional hazard assumption is violated.
BED10: Biologically Effective Dose; CCS: Charlson Comorbidity Score; COPD: Chronic Obstructive Pulmonary Disease; Dmax: maximum point dose; Dmean: mean
dose; Dmin: minimum point dose; D..p: dose to .. percent of the PTV; FEV1: Forced Expiratory Volume in 1 second; NSCLC: non-small cell lung cancer; PTV:
Planned Target Volume; SBRT: Stereotactic Body Radiation Therapy; UMM: upper/middle lobe or mediastinum.
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Discussion
Stereotactic treatment of central lung tumors frequently
comes with underdosage of the PTV due to nearby OARs,
however as far as we know the consequences of this under-
dosage were still unknown. Within our cohort, neither the
absolute nor the relative amount of PTV underdosage was
prognostic for a local recurrence. We did find the following
factors to be independent significantly prognostic: larger
tumor size and a lower FEV1 for local and disease recurrence
and additionally a tumor location in the lower lobe for dis-
ease recurrence.
Our reported LC rates were comparable to other studies
(Table 4) [6,9,10,14,18–25]. The univariate analysis showed
a significant correlation between a prescribed dose of
100 Gy BED10 and local tumor control. Previous studies
confirmed the importance of a higher (prescribed) radi-
ation dose on LC within the stereotactic treatment of cen-
trally located NSCLC [10,14]. Tumor size has been
frequently analyzed as a prognostic factor for local recur-
rence in patients with NSCLC treated with SBRT, but data
is conflicting [26]. Concerning studies only including cen-
tral lung tumors, tumor size has been analyzed within one
small study without finding a correlation [6]. The authors
stated that the study was underpowered due to the small
number of events. For the same reason other central lung
tumor studies were unable to define any prognostic fac-
tors [27,28]. However, within multiple combined (including
both central and peripheral tumors) studies, larger tumor
size was prognostic for local recurrence in SBRT treatment
as in our analysis [9,14,20,21,25]. Only 2 studies analyzed
FEV1 as a prognostic factor, but without describing the
same correlation we found [19,21]. However, a poor FEV1
is commonly caused by smoking and it is known that peo-
ple who smoked had worse outcomes [29]. Within our ana-
lysis, the incidence of local recurrences was almost similar
between the ultracentral and central tumors and the LC
rates were not significantly different. Other studies com-
paring LC for patients with an ultracentral versus a central
lung tumor after SBRT confirmed these equal LC
rates [30–32].
Prognostic factors for DFS after SBRT in NSCLC have rarely
been published. Several studies have only reported local-,
regional- and distant control as separate analyses while
others have reported only the DFS rates without possible
prognostic factors. Three studies have confirmed our out-
come that a larger tumor is correlated with disease recur-
rence, 2 analyzing DFS [6,25] and one analyzing distant
control [21]. FEV1 has been analyzed in one study focusing
on DFS and one on distant control, but was not prognostic
in either study [19,21]. Chang et al. investigated COPD for
potential association with DFS, but did not find a relation
[28]. In our cohort, patients with tumors located in the lower
lobe were at higher risk for disease recurrence, this was con-
firmed by another study [33]. An explanation can be the
more frequent upstaging due to unsuspected nodal involve-
ment in lower lobe tumors that is seen after surgery. This
can also be the case in tumors treated with SBRT [34]. With



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































local and distant control for central tumors compared with
peripheral tumors [23,25]. There was no significant correl-
ation between dose and disease control in our study, which
is comparable to other studies analyzing dosimetry as prog-
nostic factor for DFS or distant control [19,21,28,35].
Although some characteristics had missing values, we did
enter all characteristics having a p-value of <.20 into the
MVA. This resulted in an analysis based on 196 patients with
an adequate number of events (23 local failure events and
66 disease progression events) to run a reliable MVA.
However, next to the prognostic patient characteristics, we
did not find a relation between local recurrence and dose to
the PTV or PTV underdosage. The number of events may be
too small for an elaborate MVA and it may not be able to
identify a potentially weaker association between dosimetric
factors and disease control. In the MVA for both LC and DFS,
we only included tumor size and not PTV volume and dis-
ease stage as these factors were highly correlated. Of the 3
factors tumor size was chosen as it is the most clinical rele-
vant characteristic. A limitation of this study is its retrospect-
ive nature. Additionally, as mentioned in the tables, some
characteristics did not fulfill the proportional hazard assump-
tion in the Cox regression. Hence, the parameter being esti-
mated by the Cox procedure may not be a meaningful
measure of the between group difference and should be fur-
ther examined in future research.
This analysis showed that stereotactic treatment of cen-
trally located NSCLC resulted in promising local control
and disease free survival rates which are partly determined
by the size of the tumor, the FEV1 and in case of DFS also
by the lobe location of the tumor. Although underdosage
of the PTV was not prognostic for a local recurrence, the
balance between a high local tumor dose and respecting
the dose constraints of the organs at risk will remain
important in the stereotactic treatment of central lung
tumors.
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